225 related articles for article (PubMed ID: 12433802)
1. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.
Wang JS; Neuvonen M; Wen X; Backman JT; Neuvonen PJ
Drug Metab Dispos; 2002 Dec; 30(12):1352-6. PubMed ID: 12433802
[TBL] [Abstract][Full Text] [Related]
2. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil.
Shitara Y; Hirano M; Sato H; Sugiyama Y
J Pharmacol Exp Ther; 2004 Oct; 311(1):228-36. PubMed ID: 15194707
[TBL] [Abstract][Full Text] [Related]
3. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions.
Ogilvie BW; Zhang D; Li W; Rodrigues AD; Gipson AE; Holsapple J; Toren P; Parkinson A
Drug Metab Dispos; 2006 Jan; 34(1):191-7. PubMed ID: 16299161
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
[TBL] [Abstract][Full Text] [Related]
5. Effects of fibrates on metabolism of statins in human hepatocytes.
Prueksaritanont T; Tang C; Qiu Y; Mu L; Subramanian R; Lin JH
Drug Metab Dispos; 2002 Nov; 30(11):1280-7. PubMed ID: 12386136
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.
Jaakkola T; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):44-51. PubMed ID: 16867170
[TBL] [Abstract][Full Text] [Related]
7. Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis.
Kaspera R; Naraharisetti SB; Tamraz B; Sahele T; Cheesman MJ; Kwok PY; Marciante K; Heckbert SR; Psaty BM; Totah RA
Pharmacogenet Genomics; 2010 Oct; 20(10):619-29. PubMed ID: 20739906
[TBL] [Abstract][Full Text] [Related]
8. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
Prueksaritanont T; Ma B; Tang C; Meng Y; Assang C; Lu P; Reider PJ; Lin JH; Baillie TA
Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754
[TBL] [Abstract][Full Text] [Related]
9. Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations.
Filppula AM; Laitila J; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2011 May; 39(5):904-11. PubMed ID: 21289076
[TBL] [Abstract][Full Text] [Related]
10. Studies to further investigate the inhibition of human liver microsomal CYP2C8 by the acyl-β-glucuronide of gemfibrozil.
Jenkins SM; Zvyaga T; Johnson SR; Hurley J; Wagner A; Burrell R; Turley W; Leet JE; Philip T; Rodrigues AD
Drug Metab Dispos; 2011 Dec; 39(12):2421-30. PubMed ID: 21911547
[TBL] [Abstract][Full Text] [Related]
11. Interaction between fibrates and statins--metabolic interactions with gemfibrozil.
Fujino H; Yamada I; Shimada S; Hirano M; Tsunenari Y; Kojima J
Drug Metabol Drug Interact; 2003; 19(3):161-76. PubMed ID: 14682608
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 2C8 (CYP2C8)-mediated hydroxylation of an endothelin ETA receptor antagonist in human liver microsomes.
Ma B; Subramanian R; Schrag ML; Rodrigues AD; Tang C
Drug Metab Dispos; 2004 May; 32(5):473-8. PubMed ID: 15100167
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate.
VandenBrink BM; Foti RS; Rock DA; Wienkers LC; Wahlstrom JL
Drug Metab Dispos; 2011 Sep; 39(9):1546-54. PubMed ID: 21697463
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8.
Tornio A; Pasanen MK; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2005 Aug; 97(2):104-8. PubMed ID: 15998357
[TBL] [Abstract][Full Text] [Related]
15. A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement.
Kazmi F; Barbara JE; Yerino P; Parkinson A
Drug Metab Dispos; 2015 Apr; 43(4):523-33. PubMed ID: 25595597
[TBL] [Abstract][Full Text] [Related]
16. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.
Wang JS; DeVane CL
Drug Metab Dispos; 2003 Jun; 31(6):742-7. PubMed ID: 12756206
[TBL] [Abstract][Full Text] [Related]
17. Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes.
Mukai Y; Senda A; Toda T; Hayakawa T; Eliasson E; Rane A; Inotsume N
Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):493-8. PubMed ID: 25424246
[TBL] [Abstract][Full Text] [Related]
18. Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response.
Filppula AM; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2013 Jan; 41(1):50-9. PubMed ID: 23028140
[TBL] [Abstract][Full Text] [Related]
19. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.
Sakaeda T; Fujino H; Komoto C; Kakumoto M; Jin JS; Iwaki K; Nishiguchi K; Nakamura T; Okamura N; Okumura K
Pharm Res; 2006 Mar; 23(3):506-12. PubMed ID: 16388406
[TBL] [Abstract][Full Text] [Related]
20. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively.
Wen X; Wang JS; Backman JT; Laitila J; Neuvonen PJ
Drug Metab Dispos; 2002 Jun; 30(6):631-5. PubMed ID: 12019187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
